Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2005

View Archived Issues

LXR agonist induces regression of atherosclerotic lesions in preclinical model

Group III mGluRs agonist shows promise in the treatment of neuropathic pain

Metabasis Therapeutics extends and expands Merck & Co. hepatitis C collaboration

MT-100 recommended for approval in U.K.

Encouraging findings from phase I studies of GRC-3886

Endpoints met in first stage of CoFactor phase II colorectal cancer study

GlycoGenesys advances development of GCS-100LE

Alnylam initiates program to develop RNAi therapeutics for spinal cord injury

UroVysion DNA probe assay approved

Millennium and UCB Pharma collaborate on antibody inflammation programs

Nektar and Zelos Therapeutics collaborate on inhaleable Ostabolin-C

Positive phase I/II results of AVR-118 in cachectic patients with AIDS

Enrollment open in phase Ib/II study of ARQ-501 with gemcitabine

New phase I study for PYY3-36 Nasal Spray for obesity

E1-I.N.T. cleared to enter clinical trials for type 2 diabetes

Viventia completes enrollment in second phase I study of Proxinium

AMD-3100 phase III program opens enrollment

Treatment begins in phase II study of HER-2 Protein AutoVac

New clinical data on estrogen therapy and the risk of gallbladder disease in postmenopausal women

Low recurrence of ulcer bleeding found with an aspirin plus esomeprazole regimen

Deoxyhypusine synthase inhibition as a new strategy against HIV/News in Context

New opioid analgesics described in a Euroceltique patent

Zentaris researchers disclose agents for proliferative disorders

Phosphodiesterase inhibitors prepared and tested at GlaxoSmithKline

New therapies for Parkinson's disease claimed by Roche

Merck reports novel prostaglandin D2 antagonists

COX-2 inhibitors discovered by Merck team

Merck presents new DPP-IV inhibitors with potential use in diabetes

Sulfasalazine promotes recovery from liver fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...